In this discussion with Dr. Hope Rugo, we covered her study Capitello291, which led to the approval of Capivasertib in hormone receptorpositive breast cancer with AKT1, PTEN, and PIK3CA mutations, which are seen in 4050% of the cases. We touched base on sequencing of this therapy, and important clinical pearls around the side effect management associated with this drug.

#HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers

Website: http://www.oncbrothers.com/

Twitter:   / oncbrothers  

Contact us at [email protected]